Treatment of premenstrual syndrome using danazol: preliminary report of a placebo-controlled, double-blind, dose ranging study
RCT
OA: closed
CC0
⤵ 2 in-corpus citations
AI-generated summary
This placebo-controlled, double-blind study evaluated the efficacy of danazol in treating premenstrual syndrome, a condition characterized by cyclic psychological and physical symptoms that are not linked to endometriosis or adenomyosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Introduction The premenstrual syndrome (PMS) is a common condition in which a cluster of psychological and/or physical symptoms recur in the post-ovulatory phase of the cycle, subsiding with the onset of menstruation and not usually re-appearing before ovulation. The precise aetiology of PMS is obscure. Though hormone-related, no consistent hormonal defect has been shown. Whilst a variety of treatments are employed, including progesterone, dydrogesterone, pyridoxine and diuretics, proof of their value from doubleblind studies is limited. Danol (danazol) is a synthetic derivative of ethisterone which inhibits the production and activity of sex steroids by effects on the hypothalamo-pituitary gonadal system as well as on the target organ itself (Barbieri & Ryan 1981). Danol has been selected for this double-blind study in PMS following report of its potential usefulness (Day 1979).
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
Cited by (2)
References (3)
- Danazol and the premenstrual syndrome via openalex
- doi:10.1016/0002-9378(81)90611-6 via openalex
- doi:10.1136/pgmj.55.640.87 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-10T11:10:37.879400+00:00
- pubmed
- last seen: 2026-10-08T21:44:35.302430+00:00
License: CC0
· commercial use OK